stockrow
Saturday 7 November 2026
Export BPTH’s income statement to Excel — free account
Bio-Path Holdings, Inc.
BPTH Healthcare Biotechnology
- EPS
- +95.3%
- Free cash flow
- +98.7%
Quarter to March 2026, against a year earlier
0.00
0.00
NaN
Follow BPTH
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM Mar ’26 | Trend | 10 yrs | 2025e | 2026e | 2027e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | 0 | 0 | — | — | — | — | — | — | — | — | +184.6% | 40 | 40 | — | 0.0% | |
| Gross margin, % | — | 100.00 | 100.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | 0.00 | (100.0) pt | ||||||
| EBT | — | (7) | (7) | (9) | (9) | (11) | (10) | (14) | (16) | (10) | (9) | +4.9% | ||||||
| EBT margin, % | — | (51,923.08) | (18,981.08) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | +51,923.1 pt | ||||||
| Net income | — | (7) | (7) | (9) | (9) | (11) | (10) | (14) | (16) | (10) | 3 | +4.9% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | 0.56 | 1.47 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | (280.00) | (320.00) | (287.60) | (64.80) | (56.60) | (31.00) | (38.20) | (33.63) | (4.12) | (1.09) | (41.0%) | ||||||
| Cash flow | — | (351.21) | (315.75) | (204.82) | (62.91) | (56.96) | (29.49) | (41.49) | (24.13) | (4.40) | (0.17) | (42.2%) | ||||||
| Capex | — | (14.57) | (21.35) | (0.57) | 0.00 | 0.00 | (0.21) | (0.06) | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | (365.78) | (337.10) | (205.38) | (62.91) | (56.96) | (29.70) | (41.55) | (24.13) | (4.40) | (0.17) | (42.4%) | ||||||
| Book value | — | 355.17 | 320.12 | 40.74 | 158.66 | 78.33 | 75.70 | 38.94 | 0.92 | 0.06 | (0.91) | (66.0%) | ||||||
| Shares, m | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 8 | +78.6% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | 0.00 | 0.00 | — | — | — | — | — | — | — | 0.00 | 0.0 | |||||
| P/S | — | 0.00 | 0.00 | — | — | — | — | — | — | — | 0.00 | 0.0 | ||||||
| P/B | — | 14.08 | 2.62 | — | — | — | — | — | — | — | 0.00 | 8.4 | ||||||
| EV/Sales | — | 0.00 | 0.00 | — | — | — | — | — | — | — | 0.00 | 0.0 | ||||||
| EV/FCF | — | (12.39) | (1.79) | — | — | — | — | — | — | — | 0.01 | (7.1) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | (8) | (8) | (6) | (8) | (11) | (10) | (15) | (12) | (11) | (2) | +3.3% | |||||
| Capex | — | 0 | (1) | 0 | — | — | 0 | 0 | — | — | 0 | (37.1%) | ||||||
| Free cash flow | — | (8) | (8) | (6) | (8) | (11) | (10) | (15) | (12) | (11) | (2) | +2.8% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | 10 | 7 | 1 | 21 | 15 | 25 | 14 | 1 | 0 | (8) | (31.2%) | |||||
| Net debt | — | (9) | (6) | (1) | (20) | (14) | (24) | (10) | (1) | (1) | 0 | (22.9%) | ||||||
| Shareholders’ equity | — | 8 | 8 | 1 | 21 | 15 | 25 | 14 | 0 | 0 | (8) | (39.2%) | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | (58.82) | (76.57) | (150.54) | (68.23) | (55.61) | (48.51) | (65.20) | (167.56) | (278.59) | (605.50) | (219.8) pt | |||||
| ROIC | — | 0.00 | (266.59) | (2,508.76) | (823.20) | (518.44) | (387.81) | (229.24) | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | (74.76) | (98.87) | (184.88) | (77.11) | (60.19) | (51.52) | (69.99) | (220.02) | (3,325.71) | 157.01 | (3,251.0) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | 12 | 9 | 8 | 9 | 10 | 10 | 10 | 10 | 10 | — | (2.3%) | |||||
| Revenue/emp, $m | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2017 · fundamentals updated 26 Oct 2026
Bio-Path Holdings, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| LABT Lakewood-Amedex Biotherapeutics Inc. | $1.3M | — (loss-making) | — | — | n/m | −420.66% (below 0%: shrinking) | — | 0.00% | Compare |
| PTIX Atrinsic Inc. | $1.3M | 0.2× | — | +34.31% (above 0%: growing) | n/m | +46.07% (above 0%: growing) | 0.00% | 0.00% | Compare |
| BDRX Biodexa Pharmaceuticals PLC Unsponsored ADR | $1.3M | — (loss-making) | — | −32.27% (below 0%: shrinking) | +96.36% (above 0%: growing) | −0.17% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ARTL Artelo Biosciences, Inc. | $1.2M | — (loss-making) | — | — | n/m | −879.18% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| MTNB Matinas Biopharma Holdings, Inc. | $1.1M | — (loss-making) | — (loss-making) | 0.00% | n/m | +9.15% (above 0%: growing) | 0.00% | 0.00% | Compare |
| BBLG Bone Biologics Corp. | $1.1M | — (loss-making) | — | — | n/m | +9.99% (above 0%: growing) | — | 0.00% | Compare |
| VBIO Valion Bio, Inc. | $1.1M | — (loss-making) | — (loss-making) | +15.87% (above 0%: growing) | n/m | −189.01% (below 0%: shrinking) | (99.32%) | 0.00% | Compare |
| BPTH Bio-Path Holdings, Inc. | $1.1M | — (loss-making) | — (loss-making) | — | n/m | +98.68% (above 0%: growing) | 0.00% | 0.00% | |
| JAGX Jaguar Animal Health, Inc. | $950.0K | — (loss-making) | — (loss-making) | −58.88% (below 0%: shrinking) | n/m | +13.83% (above 0%: growing) | 15.84% | (620.16%) | Compare |
| Median of peers | $1.2M | — | — | 0.00% | — | +4.49% | 0.00% | 0.00% |
Pay and ownership Proxy statement filed 28 October 2024
Ownership
Directors and executive officers, together
0.72%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement